Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical product
|
| gptkbp:activeDuring |
bromelain
|
| gptkbp:approves |
gptkb:European_Medicines_Agency
|
| gptkbp:availability |
prescription only
|
| gptkbp:clinicalTrials |
Phase III
burn care completed successfully published studies follow manufacturer guidelines improved healing rates recommended for burn treatment reduced need for surgical intervention |
| gptkbp:contains |
bromelain
|
| gptkbp:contraindication |
rare
hypersensitivity to bromelain |
| gptkbp:customerFeedback |
generally positive
|
| gptkbp:diseaseResistance |
high
|
| gptkbp:drugInterdiction |
none reported
local action proteolytic activity |
| gptkbp:exportMarkets |
ongoing monitoring
|
| gptkbp:fireDepartment |
necessary before use
|
| gptkbp:firstAppearance |
2016
|
| gptkbp:formulation |
gel
biological product |
| gptkbp:hasPopulation |
adults and children
|
| gptkbp:healthcare |
available
recommended during treatment instruct on application |
| https://www.w3.org/2000/01/rdf-schema#label |
NexoBrid
|
| gptkbp:impact |
up to 14 days
wound healing |
| gptkbp:insuranceAccepted |
varies by plan
|
| gptkbp:launchSite |
apply directly to the wound
|
| gptkbp:mandates |
partial-thickness burns
|
| gptkbp:manufacturer |
gptkb:MediWound_Ltd.
|
| gptkbp:market |
2016
|
| gptkbp:marketedAs |
gptkb:MediWound_Ltd.
|
| gptkbp:offers |
varies by region
|
| gptkbp:offersCoursesIn |
gptkb:European_Union
|
| gptkbp:packaging |
single-use tubes
|
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryCompliance |
CE marked
|
| gptkbp:researchInterest |
ongoing
|
| gptkbp:route |
topical
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:services |
once daily
|
| gptkbp:sideEffect |
local irritation
|
| gptkbp:storage |
room temperature
|
| gptkbp:supplyChain |
managed_by_MediWound
|
| gptkbp:sustainabilityPractices |
environmentally conscious packaging
|
| gptkbp:triggerType |
enzymatic debridement
|
| gptkbp:usedFor |
debridement of burn wounds
|